Trivedi MH. Major Depressive Disorder in Primary Care: Strategies for Identification.J Clin Psychiatry. 2020;81(2).<\/p>\n
Roca M, Vives M, Lpez-Navarro E, Garca-Campayo J, Gili M. Cognitive impairments and depression: a critical review. Actas Esp Psiquiatr. 2015;43(5):18793.<\/p>\n
PubMed Google Scholar <\/p>\n
Roca M, Monzn S, Vives M, Lpez-Navarro E, Garcia-Toro M, Vicens C, et al. Cognitive function after clinical remission in patients with melancholic and non-melancholic depression: a 6 month follow-up study. J Affect Disord. 2015;171:8592.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Rock PL, Roiser JP, Riedel WJ, Blackwell AD. Cognitive impairment in depression: a systematic review and meta-analysis. Psychol Med. 2014;44(10):202940.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Keilp JG, Gorlyn M, Russell M, Oquendo MA, Burke AK, Harkavy-Friedman J, et al. Neuropsychological function and suicidal behavior: attention control, memory and executive dysfunction in suicide attempt. Psychol Med. 2013;43(3):53951.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Pridmore S, Auchincloss S. Preventing suicide: a global imperative. Australasian Psychiatry. 2015;23(1):812.<\/p>\n
Article Google Scholar <\/p>\n
Cipriani A, Furukawa TA, Salanti G, Chaimani A, Atkinson LZ, Ogawa Y, et al. Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis. The Lancet. 2018;391(10128):135766.<\/p>\n
Article CAS Google Scholar <\/p>\n
Rush AJ, Trivedi MH, Wisniewski SR, Nierenberg AA, Stewart JW, Warden D, et al. Acute and longer-term outcomes in depressed outpatients requiring one or several treatment steps: a STAR*D report. Am J Psychiatry. 2006;163(11):190517.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Ghio L, Gotelli S, Marcenaro M, Amore M, Natta W. Duration of untreated illness and outcomes in unipolar depression: a systematic review and meta-analysis. J Affect Disord. 2014;152154:4551.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Mrazek DA, Hornberger JC, Altar CA, Degtiar I. A review of the clinical, economic, and societal burden of treatment-resistant depression: 19962013. Psychiatr Serv. 2014;65(8):97787.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Perlis RH. Pharmacogenomic testing and personalized treatment of depression. Clin Chem. 2014;60(1):539.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Rosenblat JD, Lee Y, McIntyre RS. The effect of pharmacogenomic testing on response and remission rates in the acute treatment of major depressive disorder: a meta-analysis. J Affect Disord. 2018;241:48491.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Greden JF, Parikh SV, Rothschild AJ, Thase ME, Dunlop BW, DeBattista C, et al. Impact of pharmacogenomics on clinical outcomes in major depressive disorder in the GUIDED trial: a large, patient- and rater-blinded, randomized, controlled study. J Psychiatr Res. 2019;111:5967.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Tiwari AK, Zai CC, Altar CA, Tanner JA, Davies PE, Traxler P, et al. Clinical utility of combinatorial pharmacogenomic testing in depression: a canadian patient- and rater-blinded, randomized, controlled trial. Transl Psychiatry. 2022;12(1):101.<\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Oslin DW, Lynch KG, Shih MC, Ingram EP, Wray LO, Chapman SR, et al. Effect of pharmacogenomic testing for drug-gene interactions on medication selection and remission of symptoms in major depressive disorder: the PRIME Care Randomized Clinical Trial. JAMA. 2022;328(2):15161.<\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Perlis RH, Dowd D, Fava M, Lencz T, Krause DS. Randomized, controlled, participant- and rater-blind trial of pharmacogenomic test-guided treatment versus treatment as usual for major depressive disorder. Depress Anxiety. 2020;37(9):83441.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Rosenblat JD, Lee Y, McIntyre RS. Does pharmacogenomic testing improve clinical outcomes for major depressive disorder?: a systematic review of clinical trials and cost-effectiveness studies. J Clin Psychiatry. 2017;78(6):7209.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Brown L, Vranjkovic O, Li J, Yu K, Al Habbab T, Johnson H, et al. The clinical utility of combinatorial pharmacogenomic testing for patients with depression: a meta-analysis. Pharmacogenomics. 2020;21(8):55969.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
McCarthy MJ, Chen Y, Demodena A, Leckband SG, Fischer E, Golshan S, et al. A prospective study to determine the clinical utility of pharmacogenetic testing of veterans with treatment-resistant depression. J Psychopharmacol (Oxford England). 2021;35(8):9921002.<\/p>\n
Article Google Scholar <\/p>\n
Moher D, Liberati A, Tetzlaff J, Altman DG. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. BMJ. 2009;339:b2535.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Higgins JP, Altman DG, Gtzsche PC, Jni P, Moher D, Oxman AD, et al. The Cochrane collaborations tool for assessing risk of bias in randomised trials. BMJ. 2011;343:d5928.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Richardson MGP, Donegan S. Interpretation of subgroup analyses in systematic reviews: a tutorial. Clin Epidemiol Glob Health. 2019;7:1928.<\/p>\n
Article Google Scholar <\/p>\n
Shan X, Zhao W, Qiu Y, Wu H, Chen J, Fang Y, et al. Preliminary clinical investigation of Combinatorial Pharmacogenomic Testing for the Optimized treatment of Depression: a randomized single-blind study. Front Neurosci. 2019;13:960.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Bradley P, Shiekh M, Mehra V, Vrbicky K, Layle S, Olson MC, et al. Improved efficacy with targeted pharmacogenetic-guided treatment of patients with depression and anxiety: a randomized clinical trial demonstrating clinical utility. J Psychiatr Res. 2018;96:1007.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Han C, Wang SM, Bahk WM, Lee SJ, Patkar AA, Masand PS, et al. A pharmacogenomic-based antidepressant treatment for patients with major depressive disorder: results from an 8-week, randomized, single-blinded clinical trial. Clin Psychopharmacol Neurosci. 2018;16(4):46980.<\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Winner JG, Carhart JM. A prospective, randomized, double-blind study assessing the clinical impact of integrated pharmacogenomic testing for major depressive disorder. Discov Med. 2013;16(89):21927.<\/p>\n
PubMed Google Scholar <\/p>\n
Prez V, Salavert A, Espadaler J, Tuson M, Saiz-Ruiz J, Sez-Navarro C, et al. Efficacy of prospective pharmacogenetic testing in the treatment of major depressive disorder: results of a randomized, double-blind clinical trial. BMC Psychiatry. 2017;17(1):250.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Singh AB. Improved antidepressant remission in Major Depression via a pharmacokinetic pathway Polygene Pharmacogenetic Report. Clin Psychopharmacol Neurosci. 2015;13(2):1506.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Bousman CA, Arandjelovic K, Mancuso SG, Eyre HA, Dunlop BW. Pharmacogenetic tests and depressive symptom remission: a meta-analysis of randomized controlled trials. Pharmacogenomics. 2019;20(1):3747.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Stingl J, Viviani R, Polymorphism. CYP2D6 and CYP2C19, members of the cytochrome P450 mixed-function oxidase system, in the metabolism of psychotropic drugs. J Intern Med. 2015;277(2):16777.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Zeier Z, Carpenter LL, Kalin NH, Rodriguez CI, McDonald WM, Widge AS, et al. Clinical implementation of pharmacogenetic decision support tools for antidepressant drug prescribing. Am J Psychiatry. 2018;175(9):87386.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
Bousman CA, Hopwood M. Commercial pharmacogenetic-based decision-support tools in psychiatry. Lancet Psychiatry. 2016;3(6):58590.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Hicks JK, Bishop JR, Sangkuhl K, Mller DJ, Ji Y, Leckband SG, et al. Clinical pharmacogenetics implementation Consortium (CPIC) Guideline for CYP2D6 and CYP2C19 genotypes and dosing of selective serotonin reuptake inhibitors. Clin Pharmacol Ther. 2015;98(2):12734.<\/p>\n
Article CAS PubMed PubMed Central Google Scholar <\/p>\n
Hicks JK, Sangkuhl K, Swen JJ, Ellingrod VL, Mller DJ, Shimoda K, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):3744.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Juki MM, Haslemo T, Molden E, Ingelman-Sundberg M. Impact of CYP2C19 genotype on Escitalopram exposure and therapeutic failure: a retrospective study based on 2,087 patients. Am J Psychiatry. 2018;175(5):46370.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Sinyor M, Schaffer A, Levitt A. The sequenced treatment alternatives to relieve depression (STAR*D) trial: a review. Can J Psychiatry. 2010;55(3):12635.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Kato M, Serretti A. Review and meta-analysis of antidepressant pharmacogenetic findings in major depressive disorder. Mol Psychiatry. 2010;15(5):473500.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Szegedi A, Rujescu D, Tadic A, Mller MJ, Kohnen R, Stassen HH, et al. The catechol-O-methyltransferase Val108\/158Met polymorphism affects short-term treatment response to mirtazapine, but not to paroxetine in major depression. Pharmacogenomics J. 2005;5(1):4953.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Arias B, Serretti A, Lorenzi C, Gast C, Cataln R, Faans L. Analysis of COMT gene (val 158 Met polymorphism) in the clinical response to SSRIs in depressive patients of european origin. J Affect Disord. 2006;90(23):2516.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Kato M, Fukuda T, Wakeno M, Fukuda K, Okugawa G, Ikenaga Y, et al. Effects of the serotonin type 2A, 3A and 3B receptor and the serotonin transporter genes on paroxetine and fluvoxamine efficacy and adverse drug reactions in depressed japanese patients. Neuropsychobiology. 2006;53(4):18695.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Desta Z, Zhao X, Shin JG, Flockhart DA. Clinical significance of the cytochrome P450 2C19 genetic polymorphism. Clin Pharmacokinet. 2002;41(12):91358.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Bertilsson L. Geographical\/interracial differences in polymorphic drug oxidation. Current state of knowledge of cytochromes P450 (CYP) 2D6 and 2C19. Clin Pharmacokinet. 1995;29(3):192209.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Zhou SF. Polymorphism of human cytochrome P450 2D6 and its clinical significance: part II. Clin Pharmacokinet. 2009;48(12):761804.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Bradford LD. CYP2D6 allele frequency in european Caucasians, Asians, Africans and their descendants. Pharmacogenomics. 2002;3(2):22943.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Kunugi H, Hattori M, Kato T, Tatsumi M, Sakai T, Sasaki T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry. 1997;2(6):45762.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Bousman CA, Bengesser SA, Aitchison KJ, Amare AT, Aschauer H, Baune BT, et al. Review and Consensus on Pharmacogenomic Testing in Psychiatry. Pharmacopsychiatry. 2021;54(1):517.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Abdullah-Koolmees H, van Keulen AM, Nijenhuis M, Deneer VHM. Pharmacogenetics Guidelines: Overview and Comparison of the DPWG, CPIC, CPNDS, and RNPGx Guidelines.Frontiers in Pharmacology. 2020;11.<\/p>\n
Benitez J, Cool CL, Scotti DJ. Use of combinatorial pharmacogenomic guidance in treating psychiatric disorders. Per Med. 2018;15(6):48194.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Perlis RH, Mehta R, Edwards AM, Tiwari A, Imbens GW. Pharmacogenetic testing among patients with mood and anxiety disorders is associated with decreased utilization and cost: a propensity-score matched study. Depress Anxiety. 2018;35(10):94652.<\/p>\n
Article CAS PubMed Google Scholar <\/p>\n
Brown LC, Lorenz RA, Li J, Dechairo BM. Economic utility: combinatorial pharmacogenomics and medication cost savings for Mental Health Care in a primary care setting. Clin Ther. 2017;39(3):592602e1.<\/p>\n
Article PubMed Google Scholar <\/p>\n
Bousman CA, Forbes M, Jayaram M, Eyre H, Reynolds CF, Berk M, et al. Antidepressant prescribing in the precision medicine era: a prescribers primer on pharmacogenetic tools. BMC Psychiatry. 2017;17(1):60.<\/p>\n
Article PubMed PubMed Central Google Scholar <\/p>\n
<\/p>\n
Link: Trivedi MH. Continue reading
\nEffect of pharmacogenomics testing guiding on clinical outcomes in ... - BMC Psychiatry<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"